Immunocore Holdings plc focuses on the discovery, development, and commercialization of transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune disorders. The company's core technology, the ImmTAX (Immune mobilizing monoclonal TCRs Against X disease) platform, utilizes bispecific protein molecules that combine a high-affinity T cell receptor with an anti-CD3 antibody fragment to activate a targeted immune response. Immunocore's flagship commercial product, KIMMTRAK (tebentafusp), received FDA approval in 2022 as a first-in-class treatment for unresectable or metastatic uveal melanoma. Beyond its commercial oncology franchise, the company is advancing a robust clinical pipeline targeting other solid tumors, such as cutaneous melanoma and ovarian cancer, as well as infectious diseases like HIV and Hepatitis B. Operating globally with a primary base in Abingdon, UK, Immunocore collaborates with major pharmaceutical partners to expand the application of its TCR technology.
